Evidence map›Paper›PMID 41267827›Full record

ArticleSurgical case reports2025

A Case Report of Surgical and Postoperative Treatment for Thyroid Angiosarcoma with Pulmonary Metastasis.

Gai Inaguma, Takahiro Ichikawa, Dai Takeuchi, Yuko Takano, Madoka Iwase, Reiko Ohata, Kayoko Sugino, Mariko Asai, Yumiko Akita, Misato Yamamoto and 6 more

Abstract readCase Reports
In one paragraph

Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gai InagumaDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Takahiro IchikawaDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Dai TakeuchiDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Yuko TakanoDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Madoka IwaseDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Reiko OhataDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Kayoko SuginoDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Mariko AsaiDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Yumiko AkitaDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Misato YamamotoDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Yuri OzakiDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Nao ToriiDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Chihiro ToyodaDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Misaki HatasaDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Norikazu MasudaDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.
Toyone KikumoriDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThyroid angiosarcoma (TAS) is an extremely rare and highly aggressive cancer, representing less than 1% of all sarcomas. Typically diagnosed in individuals aged 50-80, with a higher incidence in women, TAS has a poor prognosis due to its tendency to metastasize, leading to a low 5-year survival rate. Due to its rarity, standardized treatment approaches are lacking, often involving a combination of surgery, chemotherapy, and radiation. This report presents TAS in a Japanese male. CASE PRESENTATION: A 78-year-old male with pre-existing conditions presented with a 30-year history of a slow-growing thyroid tumor that exhibited rapid enlargement 4 months prior to surgery. Initial fine-needle aspiration cytology was no malignancy. Examinations revealed a firm, poorly mobile 10 cm mass in the anterior neck, and left pleural effusion. Notably, papules developed at the aspiration site and progressively enlarged. Preoperative imaging indicated a malignant thyroid tumor, prompting a right thyroid lobectomy with resection of anterior neck muscles and overlying skin. Histological analysis confirmed a highly hemorrhagic angiosarcoma with infiltration into surrounding tissues. Immunohistochemical findings supported the diagnosis of TAS. A comprehensive genomic profiling testing yielded no specific therapeutic recommendations. Paclitaxel therapy was initiated 2 months after surgery, resulting in the shrinking of pulmonary nodules and the decreasing left pleural effusion. The patient subsequently died from septic shock due to a urinary tract infection 5 months after starting chemotherapy, without evidence of cervical recurrence or neutropenia during treatment.

conclusionsThis case highlights the perioperative management of a rare primary TAS. In the absence of established treatment guidelines, surgical resection followed by paclitaxel administration could be a potential therapeutic strategy to control disease progression. An accumulation of case reports is needed to better understand this aggressive malignancy and to facilitate the development of optimized therapeutic strategies.

Indexed as

comprehensive genome profilingpaclitaxelpulmonary metastasisthyroid angiosarcomathyroidectomy

Identifiers

PMID41267827
PMCPMC12627921

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.